Sugi Predict

Sugi Predict / Compounds / SCHEMBL30183086

SCHEMBL30183086

SCHEMBL30183086

CCCCC[C@H](O)/C=C/[C@H]1C=CC(=O)/C1=C\CCCCCC(=O)OC

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PTGER3 P43115 3/20 0.46
▸ PTGER4 P35408 2/20 0.46
▸ TRPA1 O75762 4/20 0.45
▸ NR4A2 P43354 2/20 0.45
▸ NFKB1 P19838 1/20 0.44
▸ NFKB2 Q00653 1/20 0.44
▸ RELA Q04206 1/20 0.44
▸ ALDH1A1 P00352 2/20 0.43
▸ KDM4E B2RXH2 1/20 0.43
▸ HKDC1 Q2TB90 1/20 0.43
▸ TDP1 Q9NUW8 1/20 0.43
▸ SAE1 Q9UBE0 1/20 0.43
▸ UBA2 Q9UBT2 1/20 0.43
▸ HPGD P15428 2/20 0.41
▸ MEN1 O00255 1/20 0.41
▸ LMNA P02545 1/20 0.41
▸ POLB P06746 1/20 0.41
▸ NR4A1 P22736 1/20 0.41
▸ PTPN7 P35236 1/20 0.41
▸ KMT2A Q03164 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10619455 0.91 NFKB1 (0.52) TRPA1NR4A2NFKB1NFKB2RELA
SCHEMBL10619446 0.91 NFKB1 (0.52) TRPA1NR4A2NFKB1NFKB2RELA
SCHEMBL10619862 0.89 TRPA1 (0.57) PTGER3PTGER4TRPA1NR4A2ALDH1A1
SCHEMBL14344308 0.89 TRPA1 (0.57) PTGER3PTGER4TRPA1NR4A2ALDH1A1
SCHEMBL10619859 0.89 TRPA1 (0.57) PTGER3PTGER4TRPA1NR4A2ALDH1A1
SCHEMBL10603475 0.87 NFKB1 (0.49) TRPA1NFKB1NFKB2RELAALDH1A1
SCHEMBL10772965 0.87 NFKB1 (0.49) TRPA1NFKB1NFKB2RELAALDH1A1
SCHEMBL10772968 0.87 NFKB1 (0.49) TRPA1NFKB1NFKB2RELAALDH1A1
SCHEMBL10603470 0.87 NFKB1 (0.49) TRPA1NFKB1NFKB2RELAALDH1A1
SCHEMBL10608167 0.87 NFKB1 (0.49) TRPA1NFKB1NFKB2RELAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260076990-A1 DSRNA, USE THEREOF AND PREPARATION METHOD THEREFOR TUOJIE BIOTECH SHANGHAI CO LTD (CN) 2026-03-19 — — US disclosed
US-20250332190-A1 LPA-TARGETING SIRNA AND CONJUGATE TUOJIE BIOTECH SHANGHAI CO LTD (CN) 2025-10-30 — — US disclosed
US-20250197853-A1 SIRNA TARGETING ANGIOTENSINOGEN AND PHARMACEUTICAL USE OF SIRNA TUOJIE BIOTECH (SHANGHAI) CO., LTD. (CN) 2025-06-19 — — US disclosed
CN-119183476-A Deuterated chemical modifications and oligonucleotides comprising same 上海拓界生物医药科技有限公司 2024-12-24 — — CN disclosed
EP-4467645-A1 DSRNA, USE THEREOF AND PREPARATION METHOD THEREFOR Tuojie Biotech (Shanghai) Co., Ltd. (CN) 2024-11-27 — — EP disclosed
EP-4450624-A1 LPA-TARGETING SIRNA AND CONJUGATE Tuojie Biotech (Shanghai) Co., Ltd. (CN) 2024-10-23 — — EP disclosed
EP-4435104-A1 SIRNA TARGETING ANGIOTENSINOGEN AND PHARMACEUTICAL USE OF SIRNA Tuojie Biotech (Shanghai) Co., Ltd. (CN) 2024-09-25 — — EP disclosed
CN-118591628-A DsRNA, application and preparation method thereof 上海拓界生物医药科技有限公司 2024-09-03 — — CN disclosed
CN-118541482-A DsRNA, preparation method and application thereof 上海拓界生物医药科技有限公司 2024-08-23 — — CN disclosed
CN-118541487-A DsRNA, application and preparation method thereof 上海拓界生物医药科技有限公司 2024-08-23 — — CN disclosed
WO-2023138659-A1 DSRNA, USE THEREOF AND PREPARATION METHOD THEREFOR 上海拓界生物医药科技有限公司 2023-07-27 — — WO disclosed
WO-2023138663-A1 DSRNA, USE THEREOF AND PREPARATION METHOD THEREFOR 上海拓界生物医药科技有限公司 2023-07-27 — — WO disclosed
WO-2023138650-A1 DSRNA, USE THEREOF AND PREPARATION METHOD THEREFOR 上海拓界生物医药科技有限公司 2023-07-27 — — WO disclosed
WO-2023109938-A1 DSRNA, PREPARATION METHOD THEREFOR AND USE THEREOF 上海拓界生物医药科技有限公司 2023-06-22 — — WO disclosed
WO-2023109932-A1 DSRNA AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF 上海拓界生物医药科技有限公司 2023-06-22 — — WO disclosed
WO-2023109935-A1 DSRNA, AND PREPARATION METHOD THEREFOR AND USE THEREOF 上海拓界生物医药科技有限公司 2023-06-22 — — WO disclosed
WO-2023109945-A1 DSRNA, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF 上海拓界生物医药科技有限公司 2023-06-22 — — WO disclosed
WO-2023109940-A1 LPA-TARGETING SIRNA AND CONJUGATE 上海拓界生物医药科技有限公司 2023-06-22 — — WO disclosed
WO-2023088427-A1 SIRNA TARGETING ANGIOTENSINOGEN AND PHARMACEUTICAL USE OF SIRNA 上海拓界生物医药科技有限公司 2023-05-25 — — WO disclosed
WO-2023274395-A1 NUCLEIC ACID LIGAND AND CONJUGATE THEREOF, AND PREPARATION METHOD THEREFOR AND USE THEREOF 上海拓界生物医药科技有限公司 2023-01-05 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260076990-A1 DSRNA, USE THEREOF AND PREPARATION METHOD THEREFOR APOB, RNASE1, ADAR PTGER3 3846/4885PTGER4 4589/4885TRPA1 4342/4885
US-20250332190-A1 LPA-TARGETING SIRNA AND CONJUGATE LPAR2, LPAR6, LPAR1 PTGER3 3743/4885PTGER4 4216/4885TRPA1 4428/4885
US-20250197853-A1 SIRNA TARGETING ANGIOTENSINOGEN AND PHARMACEUTICAL USE OF SIRNA AGT, AGTR1, AGTR2 PTGER3 4093/4885PTGER4 4420/4885TRPA1 4166/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback